MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

Several randomized trials have demonstrated non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations can achieve favorable clinical outcomes on treatment with EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation is considered as a predictive mark...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Li, Jiayu, Li, Xuefei, Ren, Shengxiang, Chen, Xiaoxia, Zhang, Yishi, Zhou, Fei, Zhao, Mingchuan, Zhao, Chao, Chen, Xiu, Cheng, Ningning, Zhao, Yinmin, Zhou, Caicun, Hirsch, Fred R.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2014
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4202169/
https://ncbi.nlm.nih.gov/pubmed/25277203
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items